Comparison of protective effect of protein and DNA vaccines hsp90 in murine model of systemic candidiasis
Language English Country United States Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
15954537
DOI
10.1007/bf02931297
Knihovny.cz E-resources
- MeSH
- Survival Analysis MeSH
- Candida albicans immunology MeSH
- Vaccines, DNA administration & dosage immunology MeSH
- Freund's Adjuvant MeSH
- Fungal Vaccines administration & dosage immunology MeSH
- Immunoglobulin G blood MeSH
- Injections, Intradermal MeSH
- Injections, Intramuscular MeSH
- Candidiasis prevention & control MeSH
- Disease Models, Animal MeSH
- Mice, Inbred BALB C MeSH
- Mice MeSH
- HSP90 Heat-Shock Proteins administration & dosage genetics immunology MeSH
- Antibodies, Fungal blood MeSH
- Vaccines, Subunit administration & dosage immunology MeSH
- Vaccines, Synthetic administration & dosage immunology MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Vaccines, DNA MeSH
- Freund's Adjuvant MeSH
- Fungal Vaccines MeSH
- Immunoglobulin G MeSH
- HSP90 Heat-Shock Proteins MeSH
- Antibodies, Fungal MeSH
- Vaccines, Subunit MeSH
- Vaccines, Synthetic MeSH
Preventive vaccination by a hsp90-expressing DNA vaccine and recombinant hsp90 protein vaccine, both derived from the Candida albicans hsp90 using BALB-c mouse model of systemic candidiasis, was performed. Hsp90 mRNA was cloned from a clinical isolate of C. albicans, converted to cDNA and cloned into vaccination plasmid pVAX1. Two methods of DNA application were tested: intramuscular (i.m.) and intradermal (i.d.) injection. Recombinant protein was applied by i.d. injection with Freund's adjuvant; the control groups received PBS or Freund's adjuvant only. Mice were vaccinated and after 19 d re-vaccinated. After 3 weeks, the mice were challenged with the live C. albicans in a dose of 5 x 10(6) CFU per mouse. After the challenge, the mice vaccinated i.d. with DNA vaccine survived for 39 and 64% longer compared to those receiving Freund's adjuvant and/or PBS, respectively. The i.m. application of the DNA vaccine did not provide any significant protectivity. The serum level of anti-candida-hsp90 serum IgG antibodies correlated with the survival rate in both i.d. protein and DNA vaccination approaches. We stressed the importance of specific humoral immunity in the mouse model of systemic candidiasis.
See more in PubMed
J Leukoc Biol. 2000 Aug;68(2):175-9 PubMed
Expert Opin Biol Ther. 2004 Feb;4(2):233-41 PubMed
Infect Immun. 2002 Aug;70(8):4323-8 PubMed
Folia Microbiol (Praha). 2002;47(2):105-12 PubMed
Folia Microbiol (Praha). 2002;47(3):297-301 PubMed
J Infect Dis. 1999 Jun;179(6):1477-84 PubMed
Annu Rev Immunol. 1997;15:617-48 PubMed
Anal Biochem. 1987 Apr;162(1):156-9 PubMed
Autoimmunity. 1997;26(1):33-42 PubMed
Haematologica. 2000 Nov;85(11):1172-206 PubMed
Immunol Lett. 2003 Feb 3;85(3):251-5 PubMed
Methods. 2003 Nov;31(3):232-42 PubMed
Eur J Immunol. 1995 Feb;25(2):451-8 PubMed
J Cell Biol. 1991 Nov;115(4):887-903 PubMed
Folia Microbiol (Praha). 1999;44(5):561-6 PubMed
J Infect Dis. 1995 Jun;171(6):1668-71 PubMed
Med Mycol. 2001 Aug;39(4):303-13 PubMed
Immunol Today. 1997 Apr;18(4):164-9 PubMed
Candidiasis--do we need to fight or to tolerate the Candida fungus?
